grunenthal
Maidenhead
RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist,
with a well-validated mechanism of action. The discovery of TRPV1 was awarded
the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin
may provide patients with long-lasting pain relief with a favourable safety
profile.
